NewsNovo
A $75 million at-the-market equity shelf, disclosed by Pulse Biosciences, Inc. (Nasdaq: PLSE) in an 8-K filed August 6, 2026, gives management the option to raise capital on its own schedule without locking in a price.
The facility, structured as an equity distribution agreement with Mizuho Securities USA LLC as sales agent, runs until it is drawn or terminated, leaving a dilution ceiling over shareholders for the duration.
How the at-the-market facility works Under the Sales Agreement, Mizuho will use commercially reasonable efforts to sell Pulse Biosciences common stock at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices.
Transactions may run through ordinary broker trades, block trades, or sales to or through a market maker on the Nasdaq Capital Market.
Keep reading